ENTA
Companies
NASDAQ
Enanta Pharmaceuticals Inc.
Health Care
$7.23
+$1.48 (+25.74%)
Price Chart
Overview
About ENTA
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Market Cap
$273.4M
Volume
955.4K
Avg. Volume
1.5M
P/E Ratio
-1.192946
Dividend Yield
0.00%
Employees
151.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.60
High Correlation
Volatility
High (0.75)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ENTA shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$273.4M
Volume955.4K
P/E Ratio-1.19
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 13, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025